NXT USA has reported positive results from a peer-reviewed study published in Food & Nutrition Research investigating Xeya Modern Shatavari's effect on women with PCOS.
The research shows that the standardised extract significantly improves ovarian morphology and androgen-related symptoms, with supportive improvements in hormonal balance and insulin sensitivity among reproductive-aged women from 20-35 years old.
This new publication follows a study published in July 2025 demonstrating benefits for perimenopausal women, making Xeya one of the only Shatavari ingredients with gold-standard, double-blind, placebo-controlled clinical trials in two distinct life stages.
Together, these studies position Xeya as one of the industry’s most validated solutions for women’s hormonal health.
"Many women don’t realise how deeply hormonal imbalance can influence reproductive health, metabolism and skin," said Eric Anderson, Managing Director of NXT USA.
"Xeya Modern Shatavari supports natural hormone balance, helping promote healthy ovarian function, consistent cycles and hormonal markers tied to clear skin and metabolic resilience."
Supplement brands addressing Polycystic Ovary Syndrome, or PCOS, are under pressure to deliver more than symptom cover-up.
Clinicians and consumers are actively looking for plant-based, clinically validated solutions that address ovarian health, hormones and metabolism together.
Xeya Modern Shatavari now has a published randomised, double‑blind, placebo‑controlled clinical trial in women with PCOS that directly supports this positioning.
Key outcomes of the study
The 12-week PCOS study, which studied 60 women aged 20-35 years old for 84 days, showed improvements for subjects in ovarian health, hormone balance, metabolic support, menstrual regularity and physical symptoms.
The following improvements in polycystic ovarian morphology were demonstrated:
- a 21% reduction in ovarian volume
- a 41% reduction in cyst size
- and a 20-25% reduction in follicle count.
Subjects also showed a 33.9% reduction in total testosterone and a 31.8% increase in SHBG (Sex Hormone-Binding Globulin), as well as an 18.6% improvement in LH:FSH ratio (Luteinizing Hormone:Follicle-Stimulating Hormone).
A 14% improvement in insulin sensitivity (HOMA-IR: Homeostatic Model Assessment of Insulin Resistance) was also observed.
The study also showed visible physical improvements in those taking Xeya Modern Shatavari. The researchers observed the following improvements in subjects:
- a 44% reduction in acne severity
- a 46% reduction in hirsutism
- and reductions in waist and hip circumference.
Improvements in menstrual cycle consistency over baseline were also observed.
Xeya Modern Shatavari was well-tolerated, with no serious adverse events reported.
For finished product brands, Xeya Modern Shatavari offers a differentiated, clinically substantiated ingredient that can anchor PCOS and menstrual health formulas, women’s metabolic and hormone-balance products and skin-hair/hormone “PCOS beauty-from-within” concepts.
"This approach provides a degree of validation unmatched among Shatavari suppliers," said Anderson.
"This framework turns good studies into great ones and good claims into claims that can build a supplement brand. This approach is exactly why brands choose to partner with us."
Beyond clinical rigour, Xeya is produced through a fully traceable and environmentally responsible supply chain.
The Shatavari is wildcrafted under regulated forest management, peeled and dried by local women’s cooperatives and processed using only purified water and organic ethanol.
Final extraction and manufacturing follow low-carbon, contaminant-free practices and carry globally recognised certifications, ensuring sustainability, safety and consistency from forest to formulation.
While all other Shatavari (Asparagus racemosus) formulations rely on higher daily doses, Xeya delivers significant outcomes at just 100 mg, highlighting NXT USA’s leadership in low-dose, clinically validated Shatavari formulations.
This low dose opens new formulation opportunities across capsules, gummies, powders, beverages and ready-to-eat formats, offering brand partners more flexibility and lower cost-per-serving while maintaining evidence-based efficacy.
As the market surges for botanicals targeting women’s health, new clinical findings set Xeya Modern Shatavari apart in the rapidly expanding category